Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207209 | 0.72 | LMNA (0.37) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL8524627 | 0.72 | NNMT (0.39) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL9134619 | 0.72 | SLC9A1 (0.47) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL12302294 | 0.71 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL31444061 | 0.71 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL9534063 | 0.66 | SLC9A1 (0.39) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL31474375 | 0.62 | SLC9A1 (0.48) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL4047823 | 0.61 | NQO2 (0.42) | RAB9ASMN1; SMN2KDM4ETSHRMAPT | |
| SCHEMBL16830895 | 0.60 | KDM4E (0.37) | NPC1RAB9ASMN1; SMN2LMNATP53 | |
| SCHEMBL31475796 | 0.60 | KDM4E (0.37) | NPC1RAB9ASMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476283-B2 | [6,5]—bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2152707-B1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-29 | — | — | US | disclosed |
| US-8093257-B2 | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2152707-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | NPC1 720/4885RAB9A 481/4885SMN1; SMN2 3059/4885 |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | NPC1 720/4885RAB9A 481/4885SMN1; SMN2 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.